Skip to main content
Inify Laboratories AB logo

Inify Laboratories AB — Investor Relations & Filings

Ticker · INIFY ISIN · SE0017486103 LEI · 549300306YYJ3BX3VB98 ST Human health and social work activities
Open in API
Filings indexed 341 across all filing types
Latest filing 2023-06-20 Regulatory Filings
Country SE Sweden
Listing ST INIFY

About Inify Laboratories AB

https://www.inify.com/

Inify Laboratories provides cancer diagnostics through ultramodern laboratory services within pathology. The company utilizes a fully digital, standardized, and AI-supported workflow for histopathology analysis. This integrated service model is designed to optimize the entire diagnostic process, from sample receipt to final report, ensuring high quality and significantly reduced turnaround times for clinical partners. Initially focused on prostate cancer, the company has expanded its diagnostic capabilities to include other areas such as gastroenterology. By streamlining the clinical pathway, Inify Laboratories enables healthcare providers to receive faster results, which facilitates earlier patient follow-up and treatment planning.

Recent filings

Filing Released Lang Actions
Successful launch of Inify Laboratories’ services, with first patient cases diagnosed
Regulatory Filings Classification · 95% confidence The document is a press release dated June 20, 2023, announcing the successful launch of Inify Laboratories' services and the delivery of its first patient diagnoses. It discusses operational milestones, strategic partnerships (Loomis), and future goals, including generating shareholder value. This type of announcement, focusing on operational achievements and business updates rather than formal financial statements (like 10-K or IR) or specific regulatory events (like DIRS or DIV), typically falls under a general regulatory announcement or news release. Since there is no specific category for a general operational launch announcement, and it is not a transcript (CT), earnings release (ER), or management discussion (MDA), the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal announcement subject to disclosure requirements (as noted at the end: "This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act."). The document length (4152 chars) is substantial enough to be the primary announcement, not just a link to a report (ruling out RPA).
2023-06-20 English
Framgångsrik lansering av Inify Laboratories tjänster – första patientfallen har diagnostiserats
Regulatory Filings Classification · 94% confidence The document is a press release dated June 20, 2023, announcing the successful launch of Inify Laboratories' services and the diagnosis of the first patient cases. It details operational milestones (opening the first lab, securing logistics partners, integrating AI) and strategic vision. This type of announcement, focusing on operational achievements and business updates rather than detailed periodic financial results (like 10-K or IR) or specific shareholder actions (like DIV or DVA), typically falls under a general business update or regulatory filing. Since it is a formal announcement of a significant business event (service launch) and includes a disclaimer referencing Norwegian securities law disclosure requirements, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but it reads more like a corporate news announcement. Given the options, and that it is a formal announcement of a major operational step, RNS is the most appropriate general regulatory category for non-standardized news releases, although it shares characteristics with an ER (announcing a 'launch'). However, since it is not explicitly presenting quarterly/periodical financial results highlights, RNS is safer than ER. It is definitely not a full report (10-K, IR) or a presentation (IP).
2023-06-20 Swedish
Vellykket lansering av Inify Laboratories sine tjenester, med de første pasientene diagnostisert
Regulatory Filings Classification · 94% confidence The document is a press release announcing the successful launch of Inify Laboratories' services and the diagnosis of the first patients. It details operational milestones (opening the first lab, integrating AI workflow, partnership with Loomis) and quotes the CEO and CMO regarding the company's vision and progress. This type of announcement, focusing on operational achievements and strategic updates rather than formal financial reporting (like 10-K or IR) or specific shareholder actions (like DIV or DVA), is best classified as a general announcement. Since it is not a formal regulatory filing like a 10-K, nor a specific financial release like an ER, and it details business progress, it fits best under the general 'Regulatory Filings' (RNS) category as a broad corporate announcement, or potentially an Investor Presentation (IP) if it were structured as a slide deck, but given the format, RNS is the most appropriate fallback for a press release detailing operational success. However, upon reviewing the definitions, this is a news announcement about a significant operational milestone (launch and first diagnoses) and business progress. It is not a formal financial report (10-K, IR, ER) or a specific corporate action notice (DIV, CAP). It functions as a general corporate update. Given the options, RNS (Regulatory Filings/General Announcement) is the most suitable catch-all for a press release detailing operational success that doesn't fit a more specific category like ER or MDA. It is not short enough to be a simple RPA.
2023-06-20 Norwegian
Vellykket lansering av Inify Laboratories sine tjenester, med de første pasientene diagnostisert
Regulatory Filings Classification · 100% confidence The document is a press release written in Norwegian announcing the successful launch of Inify Laboratories' services and the diagnosis of the first patients. It details operational milestones (opening the first lab, securing partnerships, integrating AI) and quotes management. It is not a formal regulatory filing like a 10-K, an earnings release (ER) which focuses on financial figures, or a detailed quarterly report (IR). Since it announces operational progress and general company news that doesn't fit the specific categories like Director's Dealing (DIRS), Capital Change (CAP), or Dividend Notice (DIV), it falls best under the general 'Regulatory Filings' category (RNS) as a standard corporate announcement, or potentially an Investor Presentation (IP) if it were a slide deck, but given the format, RNS is the most appropriate fallback for a general news release not covered elsewhere. The final sentence mentions it is 'informasjonspliktig etter verdipapirhandelloven § 5 -12' (information subject to disclosure under the Securities Trading Act), confirming it is a mandatory disclosure, but RNS serves as the general catch-all for such non-specific disclosures.
2023-06-20 Norwegian
Framgångsrik lansering av Inify Laboratories tjänster - första patientfallen har diagnostiserats
Regulatory Filings Classification · 94% confidence The document is a press release dated June 20, 2023, announcing the successful launch of Inify Laboratories' services and the diagnosis of the first patient cases. It details operational milestones (opening the first lab, securing logistics partners, integrating AI) and strategic vision. This type of announcement, focusing on operational achievements and business updates rather than detailed periodic financial results (like 10-K or IR) or specific shareholder actions (like DIV or DVA), typically falls under a general business update or regulatory filing. Since it is a formal announcement of a significant business event (service launch) and includes a disclaimer referencing Norwegian securities law disclosure requirements, it fits best as a general Regulatory Filing (RNS) or potentially an Earnings Release (ER) if it were tied to a specific reporting period, but it reads more like a corporate news announcement. Given the options, and that it is a formal announcement of a major operational step, RNS is the most appropriate general regulatory category for non-standardized news releases, although it shares characteristics with an ER (announcing a 'launch'). However, since it is not explicitly presenting quarterly/periodical financial results highlights, RNS is safer than ER. It is definitely not a full report (10-K, IR) or a presentation (IP).
2023-06-20 Swedish
Successful launch of Inify Laboratories' services, with first patient cases diagnosed
Regulatory Filings Classification · 95% confidence The document is a press release dated June 20, 2023, announcing the successful launch of Inify Laboratories' services and the delivery of its first patient diagnoses. It discusses operational milestones, strategic partnerships (Loomis), and future goals, including generating shareholder value. This type of announcement, focusing on operational achievements and business updates rather than formal financial statements (like 10-K or IR) or specific regulatory events (like DIRS or DIV), typically falls under a general regulatory announcement or news release. Since there is no specific category for a general operational launch announcement, and it is not a transcript (CT), earnings release (ER), or management discussion (MDA), the most appropriate fallback category is Regulatory Filings (RNS), as it is a formal announcement subject to disclosure requirements (as noted at the end: "This information is subject to the disclosure requirements pursuant to section 5 -12 of the Norwegian Securities Trading Act."). The document length (4152 chars) is substantial enough to be the primary announcement, not just a link to a report (ruling out RPA).
2023-06-20 English

Browse filings by year

5 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.